Detalhe da pesquisa
1.
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
N Engl J Med
; 380(24): 2295-2306, 2019 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30990260
2.
Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials.
Am J Physiol Gastrointest Liver Physiol
; 316(3): G372-G386, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30495974
3.
Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
Pharmacoepidemiol Drug Saf
; 28(12): 1620-1628, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31456304
4.
Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.
J Am Soc Nephrol
; 28(1): 368-375, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27539604
5.
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
Diabetes Obes Metab
; 19(3): 387-393, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28120497
6.
A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
BMC Health Serv Res
; 16(a): 356, 2016 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27495291
7.
Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity.
Ethn Dis
; 26(2): 221-8, 2016 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27103773
8.
Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.
Diabetologia
; 58(6): 1183-7, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25813214
9.
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
Lancet
; 382(9896): 941-50, 2013 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-23850055
10.
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
Am J Nephrol
; 40(1): 64-74, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25059406
11.
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
BMC Endocr Disord
; 14: 37, 2014 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-24742013
12.
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
Am Heart J
; 166(2): 217-223.e11, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23895803
13.
Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study.
Curr Med Res Opin
; 36(7): 1117-1124, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32338068
14.
Reliability and feasibility of methods to quantitatively assess peripheral edema.
Clin Med Res
; 7(1-2): 21-31, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19251582
15.
Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes.
Curr Med Res Opin
; 34(2): 313-318, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29022746
16.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Diabetes Care
; 29(12): 2638-43, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17130197
17.
Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.
Curr Med Res Opin
; 33(3): 553-562, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27977934
18.
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
Postgrad Med
; 128(4): 371-80, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27002421
19.
Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes.
Diabetes Ther
; 7(4): 659-678, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27734320
20.
Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis.
J Am Geriatr Soc
; 64(3): 543-52, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27000327